VC: Genizon rounds up $31M



Genizon rounds up $31M

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Genizon BioSciences
Canada

$31M
Fifth

BTF

Genizon's has DNA resources and a platform that is applicable to many stages of drug development.

Corthera
San Mateo, CA

$23M
Third

Caxton Advantage Life Sciences Fund

Corthera lead therapy is Relaxin, which is being developed to treat heart failure.

Primera Biosystems
Providence, RI

$21M
Second

Abingworth

Primera has been developing new technology related to gene expression, DNA/RNA analysis, micro RNA analysis, mutation analysis and methylated DNA analysis.

Arcion Therapeutics
Baltimore

$8.8M
First

CMEA Ventures and InterWest Partners

Arcion has been developing ARC-4558, a topical gel to treat moderate and severe pain caused by diabetic neuropathy.

Follica
Boston

$5.5M
First

Interwest Partners

Follica is developing a therapy for androgenetic alopecia and other hair follicle disorders.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.